Novel combination immunotherapy for patients with metastatic colorectal cancer

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-13 04:15 GMT   |   Update On 2022-09-13 04:15 GMT
Advertisement
A physician-scientist at City of Hope, has identified a novel combination immunotherapy regimen that demonstrated significant response in a subgroup of people with recurrent metastatic colorectal cancer.
The study Marwan Fakih, enrolled 29 patients with chemotherapy-resistant metastatic colorectal cancer who had a biomarker known as microsatellite stable (disease). The participants received a combination immunotherapy treatment consisting of ipilimumab and nivolumab, plus the targeted therapy regorafenib. Of the 22 patients whose cancer had not yet spread to the liver, more than 50% are still alive after 20 months. The seven patients whose disease had spread to the liver also received the study treatment, but they had a less favorable outcome with a median survival of seven months.
Advertisement
In a previous study, Fakih had noted there was a modest benefit when treating metastatic colorectal cancer patients without liver disease with nivolumab and regorafenib. Here, he showed that adding a CTLA-4 inhibitor, ipilimumab, appears to improve the health outcome in this subgroup of patients. (In a small sample of patients with liver metastases, the addition of CTLA-4 inhibitors did not appear to lead to major clinical benefits.)
Reference :

Giacomo Mazzoli; Romain Cohen; Sara Lonardi; Francesca Corti; Elena Elez; Marwan Fakih; Priya Jayachandran; Raphael Colle; Aakash Tushar Shah; Massimiliano Salati et al.European Journal of Cancer, DOI: 10.1016/j.ejca.2022.05.044


Full View
Tags:    
Article Source : European Journal of Cancer

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News